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isk factors for cardiovascular and cerebrovascular disease, whether they result in clinically significant vascular events or not, have been associated with pathological brain changes related to cognitive dysfunction such as vascular dementia (VaD) and Alzheimer's disease (1) (2) (3) . These same vascular risk factors (VRFs) have also been associated with more subtle forms of cognitive impairment than those associated with these brain pathologies (4) . For example, the concept of vascular cognitive impairment has been invoked to describe those patients with cognitive impairment and risk of VaD but not meeting criteria for VaD (5) .
There have been several published reviews cataloguing brain imaging changes in association with risk factors for cardiovascular and cerebrovascular disease. However, these reviews typically include a substantial number of studies with subjects with a history of symptomatic cardiovascular and/or cerebrovascular disease and/or events. Indeed, decline in cognitive abilities has been related directly to strokes (6) and severe cardiovascular disease in the absence of clinically identified stroke (7, 8) , particularly in cases of heart failure (9) . By extrapolation, these same subjects harbor significant brain dysfunction directly related to strokes and cardiovascular disease. of the study cohort had a diagnosis of coronary artery disease, myocardial infarction, congestive heart failure, and peripheral vascular disease and if a <5%
prevalence rate was present in the sample, no subanalyses were carried out excluding subjects with those diagnoses or no statistical adjustment was performed to control for the effects of these diagnoses; and 6) no statistical correction for the effects of age, sex, and the effects of other VRFs not the primary focus of investigation.
SEARCH STRATEGY. Studies were identified by searching the following electronic databases: MED-
LINE, CINAHL, and Cochrane Database of Systematic
Review using the following search terms: "vascular risk factor," "hypertension," "diabetes," "obesity," "hyperlipidemia," "smoking," "metabolic syndrome," "brain," "imaging," "magnetic resonance imaging (MRI)," "fMRI," "DTI", "PET," and "computed tomography (CT)." References of review papers were searched to identify studies that might have been overlooked in the initial search. Six of the authors (J.F., C.T., G.G., H.D., L.C., and P.D.) reviewed abstracts of all citations from the search and the full papers for inclusion. The final decision to include studies was on the basis of the inclusion and exclusion criteria and a review of the full text papers by the primary author (J.I.F.).
DATA EXTRACTION.
We developed a data extraction sheet and had 6 review authors (J.F., C.T., G.G., H.D., L.C., P.D.) extract the following data from included studies with the primary author (J.I.F.), checking the extracted data for its integrity and accuracy: 1) number of study subjects in each group; 2) demographic characteristics of subjects (i.e., age, sex, ethnicity);
3) VRF being assessed; 4) presence of symptomatic cardiovascular, cerebrovascular, or peripheral vascular disease; 5) whether prevalence of vascular disease $5%, was a subanalysis performed excluding those subjects with disease or were statistical analyses performed to control for the effects of vascular disease; 6) the presence of other VRFs and, if present, was a subanalysis performed excluding those subjects with multiple risk factors or were statistical analyses performed to control for the effects of the other VRFs; 8) onset (i.e., mid-life, late life) and length of exposure to risk factor; 9) treatment of VRFs, analyses of effects of treatment; 9) imaging modality; 10) all structural and functional imaging outcomes; and 11) correlations between imaging variables and neuropsychological test performance.
RESULTS
To better understand the data presented in this review, a summary of neuroimaging acronyms referenced herein is provided in Table 1 report no volume loss (17, 18) . In addition, some studies report higher DBP associated with greater brain GM volume loss over time (15), whereas others report higher SBP associated with greater volume loss (19) .
When considering the effects of pharmacological treatment of HTN on brain GM volumetric changes, 2 outcomes emerge: 1) pharmacological treatment of HTN fails to prevent increased brain GM loss over time (14, 16, 19) (14) and a variable pattern of MRI-identified WM hyperintensity (WMH) increases with respect to overall burden and location in the brain (11, 13, 14, 19) . Tc-HMPAO ¼ technetium 99 hexamethyl-propyl creatinine oxime.
Friedman et al. However, these results are confounded by the The association between higher total cholesterol with lower rCMRglu in the precuneus, prefrontal, parietotemporal, and frontal regions remain significant after controlling for statin use (limited data).
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Friedman et al. while performing the same tests (27) . These data suggest that regional blood flow changes in the brains of hypertensive patients performing cognitive tests redistribute to alternate brain regions to maintain successful performance of these cognitive tests. This 
II. DIABETES MELLITUS.
A total of 13 published imaging studies of the brain in association with DM are included in this review (Online Table 2 ). Table 2 Table 2 ). The increased connectivity in 2 of the networks of diabetic patients without microangiopathy (which we may consider an earlier stage in the course of diabetes compared with diabetic patients with microangiopathy) has also been observed early in the process of other pathological brain states such as multiple sclerosis and mild cognitive impairment (47, 48) . One explanation for this early-stage increased connectivity is that it is a compensatory reaction characterized by functional reorganization in attempts to maintain cognitive functions, occurring in response to early subtle brain damage. Indeed, as the severity of multiple sclerosis increases, brain network connectivity decreases (48).
III. ADIPOSITY. A total of 15 published imaging studies of the brain in association with measures of adiposity are included in this review (Online Table 3 ). Table 3 ). Interestingly, some investigations report significant brain GM volume reductions in those considered obese (BMI S30) (51), whereas others report significant brain GM volume reductions in those considered simply overweight (BMI >25) (52, 55) . Indeed, the magnitude of cognitive impairment is associated with the magnitude of brain GM volume loss volume in those regions significantly affected by increased adiposity (53).
Finally, a higher BMI has been associated with decreased MRI neurochemical markers of neuronal integrity (N-acetylaspartate) in several brain GM regions (56,57) (Online Table 3 ). Table 4 ). Table 4 ). Cerebral glucose metabolic changes. Higher total cholesterol has been associated with decreased glucose metabolism in several brain regions (70) (Online Table 4 ). Use of lipid-lowering drugs had no effect on these findings (70). Moreover, a higher genetic risk of abnormal cholesterol has been associated with lower glucose metabolism in the same brain regions affected by high total cholesterol (71).
V. SMOKING. A total of 12 published imaging studies of the brain in association with smoking are included in this review (Online Table 5 Table 5 ). Among those who smoke, a greater lifetime exposure tobacco has been associated with smaller GM volume in several brain regions (73, 74) .
Smoking has also been associated with MRI indexes of reduced neuronal integrity in the hippocampus Table 5 ). Neurochemical and receptor changes. Monoamine oxidase B levels have been shown to be reduced in the brains of smokers compared with nonsmokers (80, 81) . In addition, nicotinic acetylcholine receptor density has been shown to be greater in several brain regions in smokers compared with nonsmokers (82) (Online Table 5 ). Smokers acutely exposed to cigarettes show greater post-smoking imaging indexes of increased dopamine release in several brain regions compared with smokers with no acute exposure (83) .
VI. METABOLIC SYNDROME. A total of 7 published imaging studies of the brain in association with MetS are included in this review (Online Table 6 ). Table 6 ).
Structural
Functional brain changes. Brain regional activation (fMRI) changes. MetS has been associated with reduced activation of several brain regions in patients performing cognitive tasks, detected by fMRI (90) . Moreover, lower activation of these brain regions was associated with poorer performance on these cognitive tasks (90) (Online Table 6 ). Finally, these findings remained significant after controlling for the use of all medications used to treat components of MetS (90) .
DISCUSSION
The results of this systematic review demonstrate that patients without symptomatic cardiovascular, cerebrovascular, or peripheral vascular disease but harboring risk factors for these diseases show significant structural and functional brain imaging changes (Table 1) . Specifically, the risk factors of HTN, DM, increased adiposity, hyperlipidemia, and smoking are all independently associated with brain imaging changes. Moreover, the presence of an increasing number of individual VRF appears to increase the magnitude of these brain imaging changes as implied by the MetS imaging data (Online Table 6 ). An jfriedman1@rcn.com.
